111 related articles for article (PubMed ID: 2787808)
1. The influence of fever on the pharmacokinetics of pranoprofen in elderly subjects.
Fujimura A; Kajiyama H; Ebihara A
J Clin Pharmacol; 1989 Jun; 29(6):500-3. PubMed ID: 2787808
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of pranoprofen in the elderly.
Kajiyama H; Fujimura A; Ebihara A; Hino Y
Int J Clin Pharmacol Res; 1991; 11(3):123-7. PubMed ID: 1809698
[TBL] [Abstract][Full Text] [Related]
3. Chronopharmacokinetic studies of pranoprofen and procainamide.
Fujimura A; Kajiyama H; Kumagai Y; Nakashima H; Sugimoto K; Ebihara A
J Clin Pharmacol; 1989 Sep; 29(9):786-90. PubMed ID: 2478591
[TBL] [Abstract][Full Text] [Related]
4. Enhanced transdermal absorption and pharmacokinetic evaluation of pranoprofen-ethylene-vinyl acetate matrix containing penetration enhancer in rats.
Cho CW; Choi JS; Yang KH; Shin SC
Arch Pharm Res; 2009 May; 32(5):747-53. PubMed ID: 19471890
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective disposition of pranoprofen, a nonsteroidal antiinflammatory drug, in rabbits.
Nomura T; Imai T; Otagiri M
Biol Pharm Bull; 1993 Mar; 16(3):298-303. PubMed ID: 8364476
[TBL] [Abstract][Full Text] [Related]
6. Study of interaction of pranoprofen with human serum albumin: binding properties of enantiomers and metabolite.
Nomura T; Sakamoto K; Imai T; Otagiri M
J Pharmacobiodyn; 1992 Oct; 15(10):589-96. PubMed ID: 1494108
[TBL] [Abstract][Full Text] [Related]
7. Species differences in absorption, metabolism and excretion of pranoprofen, a 2-arylpropionic acid derivative, in experimental animals.
Arima N; Kato Y
J Pharmacobiodyn; 1990 Dec; 13(12):739-44. PubMed ID: 2098547
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal physiology-regulated dogs for bioavailability evaluation of an oral controlled-release dosage form composed of pulsatile release granules.
Sagara K; Yamada I; Matsuura Y; Kawata M; Shibata M
Biol Pharm Bull; 1996 Sep; 19(9):1184-8. PubMed ID: 8889038
[TBL] [Abstract][Full Text] [Related]
9. Probenecid-induced changes in the clearance of pranoprofen enantiomers.
Imai T; Nomura T; Otagiri M
Chirality; 2003 May; 15(4):318-23. PubMed ID: 12666238
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose.
Niopas I; Georgarakis M; Sidi-Frangandrea V; Chrisanthopoulos C; Liara E
Eur J Drug Metab Pharmacokinet; 1995; 20(4):293-6. PubMed ID: 8983935
[TBL] [Abstract][Full Text] [Related]
11. Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration.
Abrego G; Alvarado H; Souto EB; Guevara B; Bellowa LH; Parra A; Calpena A; Garcia ML
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):261-70. PubMed ID: 25681744
[TBL] [Abstract][Full Text] [Related]
12. [Effects of pre-instilled mydriatics on the intraocular concentration and anti-inflammatory action of topical 0.1% pranoprofen (2)--Study on multiple dosing].
Ogawa T; Ohara K; Shimizu H
Nippon Ganka Gakkai Zasshi; 1992 Sep; 96(9):1079-84. PubMed ID: 1414697
[TBL] [Abstract][Full Text] [Related]
13. In vitro, ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration.
Cañadas C; Alvarado H; Calpena AC; Silva AM; Souto EB; García ML; Abrego G
Int J Pharm; 2016 Sep; 511(2):719-27. PubMed ID: 27480398
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tiaprofenic acid in children after a single oral dose.
Bertin L; Rey E; Pons G; Mathiot JL; Richard MO; Chrétien P; Saint-Maurice C; Moran C; Ginisty D; Olive G
Eur J Clin Pharmacol; 1991; 41(3):251-3. PubMed ID: 1748142
[TBL] [Abstract][Full Text] [Related]
15. [Effects of pre-instilled mydriatics on the intraocular concentration and anti-inflammatory action of topical 0.1% pranoprofen].
Ogawa T; Ohara K; Ohira M
Nippon Ganka Gakkai Zasshi; 1988 Sep; 92(9):1510-9. PubMed ID: 3265023
[No Abstract] [Full Text] [Related]
16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
17. Pranoprofen quantification in ex vivo corneal and scleral permeation samples: Analytical validation.
Cañadas-Enrich C; Abrego G; Alvarado HL; Calpena-Campmany AC; Boix-Montañes A
J Pharm Biomed Anal; 2018 Oct; 160():109-118. PubMed ID: 30077069
[TBL] [Abstract][Full Text] [Related]
18. [The pharmacokinetics of pranoprofen in humans].
Yoshio I; Iwata A; Isobe M; Takamatsu R; Higashi M
Yakugaku Zasshi; 1990 Jul; 110(7):509-15. PubMed ID: 2231310
[TBL] [Abstract][Full Text] [Related]
19. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.
Karim A
J Clin Pharmacol; 1996 Nov; 36(11):985-97. PubMed ID: 8973987
[TBL] [Abstract][Full Text] [Related]
20. [Effects of pre-instilled mydriatics on the intraocular concentration and anti-inflammatory action of topical 0.1% pranoprofen (3)--study on permeability factor].
Ogawa T; Ohara K; Shimizu H
Nippon Ganka Gakkai Zasshi; 1992 Nov; 96(11):1379-86. PubMed ID: 1476068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
